BTN3A1 and neoplasm: The downregulated BTN3A1 may be associated with the decrease of tumor‐infiltrating immune cells such as CD8+ T cells, dendritic cells, γδ T cells, and NK cells, leading to suppression of tumor inhibition effects and worse prognosis of patients.